THREAD: How do patients with #Alzheimer's disease & related #dementias (ADRD) fare in Medicare Advantage (MA) managed care plans, compared to traditional #Medicare (TM)?

Our new blog covers studies led by @nbcoe1 ( @PennPARC) exploring this. Read on! https://ldi.upenn.edu/healthpolicysense/costs-and-outcomes-patients-dementia-medicare-advantage-plans

One @nbcoe1 study found that Traditional #Medicare beneficiaries were more likely to switch to #MedicareAdvantage plans in the subsequent 2-3 years, but MA beneficiaries were more likely to stay in MA plans. https://ldi.upenn.edu/healthpolicysense/costs-and-outcomes-patients-dementia-medicare-advantage-plans

Another study compared patients with ADRD in MA and TM, finding that MA patients had:
• Fewer medical visits
• Fewer outpatient hospital visits
• Fewer long-term care admissions
• No differences in satisfaction w/ care or self-reported health status https://ldi.upenn.edu/healthpolicysense/costs-and-outcomes-patients-dementia-medicare-advantage-plans

TM beneficiaries may benefit from MA plans, even without enrolling in them.

@nbcoe1 & colleagues found that the growth in MA plan penetration is associated with per-capita spending in TM, especially among individuals with a high #comorbidity burden. https://ldi.upenn.edu/healthpolicysense/costs-and-outcomes-patients-dementia-medicare-advantage-plans

This body of work is especially important & timely as #Medicare's open enrollment period begins.

Read the whole blog covering the series of @nbcoe1's studies on our website https://ldi.upenn.edu/healthpolicysense/costs-and-outcomes-patients-dementia-medicare-advantage-plans